ATTUALI APPROCCI TERAPEUTICI Dott. L. Trentin
|
|
- Emily Melton
- 5 years ago
- Views:
Transcription
1 II SESSIONE: LLC dalla Biologia alla Clinica ATTUALI APPROCCI TERAPEUTICI Dott. L. Trentin CONVEGNO INTERREGIONALE SIE PADOVA, 12 maggio 2011 Predicting clinical outcome in CLL: how and why survival from diagnosis of 2474 Mayo Clinic patients diagnosed with CLL since January 1995 as compared with the agematched general Minnesota population survival from diagnosis of 1282 Mayo Clinic patients diagnosed with Rai stage 0 CLL since January 1995 as compared with the age matched general Minnesota population Tait D. Shanafelt Factors affecting the prognosis of CLL patients IgVH ZAP70 CD38 Cytogenetics Telomere length Telomerase TK Response β2-microglobulin Patient-related Disease-related Treatment related BIOMARKERS Age Gender Performance status/comorbilities Stage Marrow failure Transformation Immunodeficiency/autoimmunity Biomarkers Type of therapy Minimal residual disease status Telomerase Activation of telomerase is essential for unlimited cell growth and plays a critical role in tumorigenesis Telomerase activity is significantly higher in B-CLL patients with progressive disease than in patients with stable disease Telomerase expression in B-cell chronic lympocytic leukemia predicts survival and delineates subgroups of patients with the same IgVH mutation status and different outcome Terrin et al., Leukemia pazienti con LLC sono stati valutati per Telomerasi 1. Determinazione di telomerasi e lunghezza dei telomeri 2. Analisi dei dati e comparazione con - citogenetica - SHM - ZAP70 e CD38 SHM muta) non muta) CD38 pos neg % % Citogene)ca Alterata/normale del 11, 17 del / Time to first treatment 11q- 17p q- normal- ZAP70 pos neg Doubl.)me <6mesi 11.3 tris M/F 67/33
2 Telomerasi Telomerasi Time to first treatment AT>, TS< AT>, TS> AT: TELOMERASE TS: TELOMERE LENGHT AT<, TS> AT<, TS< CLL therapy timeline Goals of CLL therapy overtime 5% 5% Alkylatinng agents -Chlorambucil -Cyclophosphamide % Purine analogs -Fludarabine -Pentostatin -Cladibrin 35% Purine analogs and alkylators 50-70% Chemoimmunotherapy 1970 Palliation 1980 Palliation, Higher Response rate ,, PFS Freedom from progression 2010 PFS, MRD- F as first line treatment in CLL at M.D. Anderson Cancer Center F as first line treatment in CLL at M.D. Anderson Cancer Center Overall survival after response Time to progression after response FL-cytometry neg Pneg P lowpos Ppos FL-cytometry pos Tam C S et al. Blood 2008;112: Tam C S et al. Blood 2008;112:
3 Definition of complete remission Response definition after treatment for patients with CLL general practice - blood lymphocytes < 4000/ml - BM lymphoid cells < 30% * MRD+ MRD- In clinical trials with as an endpoint: -CT negative -MRD assessment -BM biopsy PR MRD+ MRD- : all the criteria have to be met, and patients have to lack disease-related constitutional symptoms; PR: at least 2 of the criteria of group A plus one of the criteria of group B have o be met; SD is absence of PD and failure to achieve at least a PR; PD: at least one of the above criteria of group A or group B has to be met. Hallek et al., Blood 2008 Improved PFS in MRD negative patients Fludarabine-Based Regimens in Previously Untreated Chronic Lymphocytic Leukemia Reference Regimen Phase No Pts ORR Mean PFS (Months) Median OS (Months) Johnson, 1996[155] Flu III NR NR CAP Rai, 2000 [169] Flu III CLB Flu + CLB N/A 55 Leporrier, 2001[173] Flu III CHOP CAP Flinn, 2000 [182] Flu + Cy II N/A N/A O'Brien, 2001[183] Eich horst, 2006[93] p=0.2 Flu + Cy II NR NR Flu III NR Flu NR Cy Flu + Cy NR Catv osky, 2005[202] CLB III N/A N/A Flu N/A N/A Flu + Cy N/A N/A Moreton et al. JCO 2005 Byrd, 20 03[232] Flu + Ritu x Ran II NR NR Flu th en Ritu x NR NR Rai et al., NEJM 2000 Keatin g, Flu + Cy + II NR NR What is the impact of therapy on and PFS? CLL8 Study Chlorambucil Cam path Ben da Fludarabine Fludarabine Cyclophospahamide RFC PFS PFS Hallek et al., Lancet 2010
4 CLL8 STUDY CLL8 STUDY Progression free survival P<.0001 FC R-FC Proportion surviving P=.012 FC R-FC Hallek et al., Lancet 2010 Hallek et al., Lancet 2010 REACH TRIAL REACH TRIAL P<.001 R-FC FC Robak et al., JCO 2010 Robak et al., JCO 2010 CLL therapy: open questions after CLL8 and REACH trial CLL therapy: open questions after CLL8 and REACH trial 1. Therapy for unfit patients 2. How to improve current treatments 3. Therapy in relapsed/refractory disease 4. Therapy for high risk CLL 5. Maintenance therapy for CLL 1. Therapy for unfit patients 2. How to improve current treatments 3. Therapy in relapsed/refractory disease 4. Therapy for high risk CLL 5. Maintenance therapy for CLL
5 Definition of Ultra High-Risk Chronic Lymphocytic Leukemia OS in High-Risk Chronic Lymphocytic Leukemia no CLL8 trial Zenz et al. J Clin Oncol Stilgenbauer and Zenz, Hematology 2010 Refractory CLL Refractory CLL to Disease that fails to respond to a therapy ( / PR not achieved) Disease progressed within 6 months in patients who had achieved / PR Patients progressing or relapsing shortly (within 12 months) after stem-cell transplantation NCI IWCLL Guidelines 2008 Chlorambucil Fluda Fluda + Cytoxan Fluda-Rituxan RFC Treatment becomes more difficoult when aggressive therapies are used upfront Fludarabine in Combination with Alemtuzumab in Relasped/Refractory CLL: Phase II Trial Response to Alemtuzumab in Relapsed/Refractory CLL (N=91) Partial response 19% 18/91 (20%) MRD negative 46% 35% No response Complete Remission T. Elter et al., J. Clin. Oncol. 23: 7024 (2005) P. Moreton et al., J. Clin.Oncol. 23: (2005)
6 Limitations of Alemtuzumab German CLL Study Group CLL2H Trial Alemtuzumab sc. in fludarabine-refractory Patients Treatment: sc alemtuzumab 30 mg TIW, 12 weeks 60 PR Response (%) Toxicity - Fever - Rigors - Immunosuppression - Infections Lymphadenopathy all 17p13 11q23 others Cytogenetics VH unmut S. Stilgenbauer et al., J. Clin. Oncol. 27: 3994 (2009) Consolidation with alemtuzumab improves progression-free survival in CLL patients CMV reactivation Rationale for using MoAbs in combinations Variable expression of epitopes on CLL B cells of individual patients Synergistic activity in anatomic compartments (Rituxan/Campath: Lymph nodes/marrow) Engagement of distinct intracellular signaling pathways resulting in apoptotic cell death C.D. Schweighofer et al., Br. J. Haematol. 144: 95 (2008) Fludarabine, Cytoxan, Alemtuzumab and Rituximab (CFAR) in High-Risk CLL Combinations using Fludarabine and Campath T. Robak, Blood 115: (2010)
7 HSC Transplantation Autologous SCT Allogeneic SCT RIC Allogeneic SCT Is a procedure with evidence-based efficacy in poor-risk CLL Is a reasonale option for younger patients - with non-response or early relapse after purine analogues; - with p53 abnormalities and treatment indication; - with relapse within 24 months after having achieved a response with intensive treatment, including autologous transplantation Transplant strategies may vary on an individual basis (choice of conditioning, etc.) Limitations of Transplantation Procedures Advanced age of many CLL patients Comorbilities High Transplant Related Mortality and QoL-related problems (GvHD) Best salvage and conditioning regimens not determined Ultra High-Risk Chronic Lymphocytic Leukemia 17p-/TP53 mutation (treatment indication, 1 or>treatment line) F-refractory (no PR/ or PR/< 6 months) Refractory to Fludarabine and Alentuzumab Short PFS< 24 (-36) months after (or similar regimen, e.g. P, FR, BR), And absnce of 17p-/TP53 mutation (exclude clonal evolution by retesting) Option 1: treatment in clinical trial (clinical trial of novel agents/combinations with evidence for activity) Option 2: treatment outside trial alentuzumab Ofatumumab Prior response to F (or similar) /npr: F (ORR 70%) Prior response to F (or similar) : Alternative regimens (ORR with F 30%) Consolidation (if PR/ achieved) Fit patients: allo SCT after reduced-intensity conditioning Patients not eligible for allo-sct: consolidation therapy in clinical trial New agents for CLL Monoclonal antibodies in CLL therapy
8 Ofatumumab: characteristics Human CD20 MoAb Binds to small loop of CD20 Potent lysis of B cells More effective in vitro CDC vs rituximab Effective CDC of cells expressing low CD20 FA-ref: Fludarabine-alentuzumab refractory BF-ref: Bulky fludarabine refractory Wierda et al. Blood First Edition Paper
9 Ofatumumab trials Wierda et al. Blood First Edition Paper Flavopiridol in Refractory high-risk CLL Flavopiridol in high-risk CLL 42 Patients fludarabine refractory High risk disease 30 Patients with del(17p) or del (11q) 64 Patients with Genetically High-Risk Disease 21 Patients with del(17p) 28 Patients with del(11q) 27 Patients with complex karyotype Partial Response 45% Partial Response 47% Complete Response 1,6% Median Duration Response 12 months Response in 57% Patients with del(17p) 50% Patients with del(11q) J.C. Byrd et al., Blood 109: 399 (2007) T.S. Lin et al., J. Clin. Oncol. 27: 6012 (2009)
10 Bendamustine in CLL Rituximab and Bendamustine in Relapsed/Refractory CLL Pazienti refrattari a FC Pazienti con AEA (Coombs+) Pazienti con molteplici infezioni opportunistiche Pazienti con insufficienza renale Pazienti anziani con comorbidità Pazienti (%) PR/ npr ORR = 77% (n = 62) Tutti i pazienti n = 41 ORR 71 n = 9 Fischer K. et al., Blood 112: Abs. 330 (2008) n = n = Fludarasensibilrefrattari non Fludara- IgV H 11q del mutato n = p del Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Avanced B-CLL 40 Patients (69% Fludarabine refractory) Reduction in splenomegaly 41% Complete disappearence of hepatomegaly 29% Reduction in circulating lymphocyte counts 50% Adverse events included transient hypotension, fever, fatigue, night sweats, diarrhea, nausea, vomiting, hypokalemia, cough. S.M. O Brien et al., J. Clin. Oncol. 23: 7697 (2005) Randomized phase III trial of Fludarabine plus Cyclophosphamide with or without Oblimersen in patients with relapsed or refractory CLL % fo patients alive at 36 months 70% (14/20) 45% (13/29) 7% (5/71) Fluda+CTX and oblimersen O Brien S. et al., J. Clin. Oncol. 25: (2007) 38% (3/8) 33% (15/46) Fluda + CTX PR < PR 9% (6/67) Randomized phase III trial of Fludarabine plus Cyclophosphamide with or without Oblimersen in patients with relapsed or refractory CLL 5-Year Survival Lenalidomide in CLL Lenalidomide 25mg p.o. (1 through 21 of a 28-day cycle) until progression, unacceptable toxicity,, or 45 patients; mean age 64 yrs (42-75) Rai III-IV 64% Fludarabine refractory 51% Overall Response: 47 % (58%*) Complete Response: 9 % (18%*) Partial Response: 38 % Responding patients (i.e., patients with a complete or partial response; n = 103) S. O Brien et al., J. Clin. Oncol. 27: (2009) Only 3 patients needed addition of Rituxan * Updated results A. Chanan-Khan et al., J. Clin. Oncol. 24: (2006)
11 Progression-free Survival of Patients with CLL with High-risk Cytogenetics after Lenalidomide Therapy CLL therapy: new agents (-) del(11q)(q22.3) patients; ( ) del(17p)(p13.1) patients T. Sher et al., Leuk. Lymph. 51: 85 (2010)
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More information1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationRisikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL. Michael Hallek University of Cologne
Risikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL Michael Hallek University of Cologne 100 90 80 70 60 Substantial progress in CLL therapy in one decade 50 40 complete remissions
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: January, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationMED B Form CLL. Johannes Schetelig. London 09/April/
www.ebmt.org MED B Form CLL Johannes Schetelig London 09/April/2013 Content Update on CLL (15 ) Experiment with mini MED B CLL Assessment of pre-treatment in CLL Cytogenetics in CLL What is the IGVH-Gene
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: June, 2018 Copyright (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This
More informationChronic lymphocytic leukemia is eradication feasible and worthwhile?
Chronic lymphocytic leukemia is eradication feasible and worthwhile? Gianluca Gaidano, MD, PhD Division of Hematology Department of Clinical and Experimental Medicine Amedeo Avogardo University of Eastern
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationCLL: What s New from ASH
CLL: What s New from ASH John C. Byrd, MD D. Warren Brown Chair in Leukemia Research Professor of Medicine and Medicinal Chemistry Director, Division of Hematology The Ohio State University 2 Chronic Lymphocytic
More informationA Canadian Perspective on the Management of Chronic Lymphocytic Leukemia
A Canadian Perspective on the Management of Chronic Lymphocytic Leukemia Douglas A. Stewart, MD, FRCP(C), 1 Christine Chen, MD, MEd, FRCP(C), 2 Laurie H. Sehn, MD, MPH, 3 Chaim Shustik, MD, FRCP(C) 4 1
More informationChronic Lymphocytic Leukemia: Putting New Treatment Options Into Perspective
The diagnosis of CLL, the role of prognostic factors in determining treatment goals, and new first- and second-line treatment strategies are reviewed. Spider Web_13174. Photograph courtesy of Henry Domke,
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationManagement of Patients With Relapsed Chronic Lymphocytic Leukemia
Management of Patients With Relapsed Chronic Lymphocytic Leukemia Polina Shindiapina, MD, PhD, and Farrukh T. Awan, MD Abstract The management of chronic lymphocytic leukemia (CLL) has improved significantly
More informationCLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic
CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationQuando e se è possibile e u/le o0enere una remissione completa
Quando e se è possibile e u/le o0enere una remissione completa 1) Clinical heterogeneity Disease characteris:cs Pa:ent characteris:cs 2) Modern chemoimmunotherpy approaches 3) New mechanism- based treatment
More informationLEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA
CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More informationCLL treatment algorithm and state of the art
CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups
More informationSIMPOSIO - Leucemia Linfatica Cronica: presente e futuro nella gestione del paziente refrattario
42 Congresso Nazionale SIE 18-21 ottobre 2009 - Milano Convention Centre SIMPOSIO - Leucemia Linfatica Cronica: presente e futuro nella gestione del paziente refrattario Paolo Ghia Lab of B Cell Neoplasia
More informationL approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro
L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationMolecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University
Molecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University Chronic Lymphocytic Leukaemia (CLL) Most common leukaemia in adults Diagnosis straightforward CD19+/CD5+/CD23+
More informationUnderstanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia
UNDERSTANDING AND MANAGING ULTRA HIGH-RISK HEMATOLOGICAL MALIGNANCIES Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia Stephan Stilgenbauer 1 and Thorsten Zenz 1 1 Department of
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationallosct and CLL in the BCRi era time for a study
allosct and CLL in the BCRi era time for a study Patient characteristics in BCRi studies and allosct candidates DIFFER Facts on BCRi no Cure Risk factors for shorter BCRi efficacy in MV analysis? PA-refractory
More informationPatient Selection for allogeneic stem cell transplantation in CLL KOEN VAN BESIEN, MD WEILL CORNELL MEDICAL COLLEGE, NY
Patient Selection for allogeneic stem cell transplantation in CLL KOEN VAN BESIEN, MD WEILL CORNELL MEDICAL COLLEGE, NY Topics CLL Complicated CLL Richter s transformation What did we learn about allotransplant
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationChronic Lymphocytic Leukemia: Current Concepts
Review Chronic Lymphocytic Leukemia: Current Concepts EUN-MI YU 1, ADAM KITTAI 2 and IMAD A. TABBARA 1 1 Department of Hematology/ Oncology, George Washington University, Washington, DC, U.S.A.; 2 Department
More informationChronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia Bruce D. Cheson, M.D. Head of Hematology Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C. Chronic Lymphocytic Leukemia Most common type
More informationAdverse Prognostic Features in Chronic Lymphocytic Leukemia
ONCOLOGY. Vol. 25 No. 8 REVIEW ARTICLE Adverse Prognostic Features in Chronic Lymphocytic Leukemia By Sarah Schellhorn Mougalian, MD 1, Susan O'Brien, MD 1 July 11, 2011 1 The University of Texas MD Anderson
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2018 Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA DISCLOSURES I am on
More informationLeukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington
Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationCLL: Future Therapies. Dr. Anca Prica
CLL: Future Therapies Dr. Anca Prica Treatment Options: Improved by Decade 1960 1970 1980 1990 2000 2017 5% CR 5% CR Chemo Alkylator chlorambucil or cyclophosphamide 25% CR Chemo Purine analogues Fludarabine
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationNovember 11, 2009 ONCOLOGY. Vol. 23 No. 12 Focus on Hematology Diagnosing and Treating Chronic Lymphocytic Leukemia in 2009
November 11, 2009 ONCOLOGY. Vol. 23 No. 12 Focus on Hematology Diagnosing and Treating Chronic Lymphocytic Leukemia in 2009 Matthew Kaufman, MD_Assistant Professor_Department of Medicine_Division of Hematology-
More information17p Deletion in Chronic Lymphocytic Leukemia
17p Deletion in Chronic Lymphocytic Leukemia Risk Stratification and Therapeutic Approach Andrea Schnaiter, MD, Stephan Stilgenbauer, MD* KEYWORDS CLL 17p deletion High-risk Targeted therapy BTK PI3K BH3
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationChronic Lymphocytic Leukemia. Paolo Ghia
Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela
More informationThe International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist. Other Advances in Leukemia/MDS ALL AML MDS
The Oncologist The International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist Peer-Reviewed Journal for the Practicing Oncologist/Hematologist 20 th Anniversary Overview
More informationWatch and Wait Actualities in the Treatment of Chronic Lymphocytic Leukemia
CLINICAL UPDATE HEMATOLOGY // INTERNAL MEDICINE Watch and Wait Actualities in the Treatment of Chronic Lymphocytic Leukemia Szilárd Bíró 1, István Benedek Jr 1,2, Árpád Bzduch 1, Johanna Sándor-Kéri 1,2,
More informationAngioimmunoblastic T-cell lymphoma: nobody knows what to do...
Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte
More informationDutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011
r e v i e w Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011 A.P. Kater 1,*, S. Wittebol 2, M.E.D. Chamuleau 3, M. van Gelder 4, M.H. J van Oers 1,*, on behalf of the
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationInvestigation and Management of Chronic Lymphocytic Leukemia. James Johnston
Investigation and Management of Chronic Lymphocytic Leukemia James Johnston Site Specific Clinics CLL Clinic (787-4454) Erin Elphee BN James Johnston Rajat Kumar Matt Seftel (transplant) Myeloma Clinic
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More informationPublished Ahead of Print on February 13, 2012 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on February 13, 212 as 1.12/JCO.211.36.9348 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.211.36.9348 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationGuidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia
guideline Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia David Oscier, 1 Claire Dearden, 2 Efrem Erem, 3 Christopher Fegan, 4 George Follows, 5 Peter Hillmen,
More informationGuidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)
Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at
More informationSequencing of chronic lymphocytic leukemia therapies
CHRONIC LYMPHOCYTIC LEUKEMIA Sequencing of chronic lymphocytic leukemia therapies Jacqueline C. Barrientos CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School
More informationInfectious Complications in Patients with Chronic Lymphocytic Leukemia Pathogenesis, Spectrum, Treatment
Infectious Complications in Patients with Chronic Lymphocytic Leukemia Pathogenesis, Spectrum, Treatment Vicki A. Morrison, MD Professor of Medicine, University of Minnesota Staff Physician, Sections of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 CHLORAMINOPHENE 2 mg, capsule B/30 (CIP code: 3369906) Applicant: TECHNI-PHARMA chlorambucil ATC code:
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationclinical practice guidelines
Annals of Oncology 22 (Supplement 6): vi50 vi54, 2011 doi:10.1093/annonc/mdr377 Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B. Eichhorst 1, M.
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationEfficacy of Bendamustine and rituximab in a real-world patient population
Efficacy of Bendamustine and rituximab in a real-world patient population Median follow-up 37,1 months Efficacy of bendamustine and rituximab as first salvage treatment in CLL and indirect comparison with
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationUPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD
UPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD DISCLOSURE Speaker s bureau: Pharmacyclics, Janssen, Seattle Genetics, Astra Zeneca Consultant: Juno therapeutics, Astra Zeneca, BeiGene, Pharmacyclics
More informationGVHD & GVL in the lymphoma setting: The case of CLL
GVHD & GVL in the lymphoma setting: The case of CLL Peter Dreger Dept. Internal Medicine V University of Heidelberg EBMT: SCT for CLL 2000-2010 Update January 2012 allo auto 400 350 300 250 200 150 100
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationChronic Lymphocytic Leukemia: State of the Art
14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationThe Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
Clinical Medicine Insights: Oncology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic
More informationIs there a place for allogeneic stem cell transplantation in chronic lymphocytic leukaemia in the era of the new molecules?
185 Is there a place for allogeneic stem cell transplantation in chronic lymphocytic leukaemia in the era of the new molecules? D. Selleslag, MD SUMMARY Allogeneic stem cell transplantation can cure about
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2017 Disclosures Speaker
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationTherapy of CLL - where are we going?
CCK CancerCenterKarolinska Therapy of CLL - where are we going? An update on emerging therapeutic trends and safety aspects Anders Österborg Professor of Oncology Karolinska Institute and Hospital Stockholm,
More informationMedication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru196 Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Committee Approval Date: January
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationChronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances
Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University
More informationTest Utilization: Chronic Lymphocytic Leukemia
Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.
More information